AstraZeneca is undergoing an internal transformation. The company's shares are seeing a steady rally, driven by new partnerships in
oncology, solid growth projections, and strong performance across its growth franchises. The
stock has touched an all-time high of
92.41 USD, further fuelled by CEO's bullish projections of record revenue numbers and U.S. growth. However, its UK investment plans are still on pause. Meanwhile, the stock price target has been raised severally due to high growth potential, solid valuation and important strategic moves. AstraZeneca share price has also soared following approvals of its drugs, including
Imfinzi for gastric cancer and
Koselugo. As per recent news, the company plans to list directly on the NYSE, hinting at a gradual shift away from the UK. However, AstraZeneca CEO
Pascal Soriot assured that the company isn't leaving the UK.
AstraZeneca Stocks News Analytics from Thu, 03 Jul 2025 07:00:00 GMT to Sat, 29 Nov 2025 00:44:00 GMT -
Rating 8
- Innovation 5
- Information 7
- Rumor -3
